BMO Matthew Luchini

Citing the release of new bb2121 therapy data among other growth factors, BMO analyst Matthew Luchini has upgraded bluebird bio Inc (NASDAQ: BLUE) to Outperform and raised his price target to $108. “We believe latest data shows bb2121's continued compelling efficacy, including 100 percent...